Kobo Biotech (BOM:531541) ROCE %: 0.00% (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:531541 Kobo Biotech Ltd BOM:531541
13 GF Score
Price ₹8.23
View Full Analysis

What is Kobo Biotech ROCE %?

Kobo Biotech BOM:531541 -1.91% 13 ROCE % is 0.00% as of Mar. 2025. GuruFocus rates BOM:531541 with a GF Score™ of 13/100.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Kobo Biotech's annualized ROCE % for the quarter that ended in Mar. 2025 was 0.00%.

Kobo Biotech  (BOM:531541) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Kobo Biotech ROCE % Related Terms

Kobo Biotech ROCE % Historical Data

* Premium members only.

The historical data trend for Kobo Biotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kobo Biotech ROCE % Chart

Kobo Biotech Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Kobo Biotech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Mar25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:531541
13GF Score
Kobo Biotech Ltd BOM:531541
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kobo Biotech ROCE % Calculation

Kobo Biotech's annualized ROCE % for the fiscal year that ended in Mar. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2025 )  (A: Mar. 2024 )(A: Mar. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2025 )  (A: Mar. 2024 )(A: Mar. 2025 )
=-51.312/( ( (713.935 - 1678.223) + (715.901 - 1732.487) )/ 2 )
=-51.312/( (-964.288+-1016.586)/ 2 )
=-51.312/-990.437
=5.18 %

Kobo Biotech's ROCE % of for the quarter that ended in Mar. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2025 )  (Q: Jun. 2024 )(Q: Mar. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2025 )  (Q: Jun. 2024 )(Q: Mar. 2025 )
=0/( ( (0 - 0) + (715.901 - 1732.487) )/ 1 )
=0/( ( 0 + -1016.586 )/ 1 )
=0/-1016.586
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Kobo Biotech (BOM:531541) has a ROCE % of 0.00% as of Mar. 2025.
Is Kobo Biotech's ROCE % too high?
Kobo Biotech's current ROCE % is 0.00%. Overall, Kobo Biotech has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Kobo Biotech's ROCE % compare to ZTS?
Kobo Biotech's ROCE % of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.03, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kobo Biotech's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kobo Biotech stock overvalued right now?
Kobo Biotech (BOM:531541) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. Kobo Biotech's overall GF Score™ is 13/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Kobo Biotech (BOM:531541), the current ROCE % is 0.00% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kobo Biotech Business Description

Address Saki Vihar Road, Unit 104, HYDE Park, Opposite Ansa Industrial Estate, Andheri (East), Mumbai, MH, IND, 400 072
Kobo Biotech Ltd is a pharmaceutical company. Its business comprises the manufacturing and sale of APIs (Active Pharmaceutical Ingredients) based on fermentation technology and Intermediates to pharmaceutical companies.
13GF Score

Get the complete analysis for BOM:531541

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹8.23
Price